Emil D. Kakkis
2019
In 2019, Emil D. Kakkis earned a total compensation of $6.6M as President and Chief Executive Officer at Ultragenyx Pharmaceutical, a 36% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $479,808 |
|---|---|
| Option Awards | $2,650,784 |
| Salary | $714,000 |
| Stock Awards | $2,702,000 |
| Other | $39,887 |
| Total | $6,586,479 |
Kakkis received $2.7M in stock awards, accounting for 41% of the total pay in 2019.
Kakkis also received $479.8K in non-equity incentive plan, $2.7M in option awards, $714K in salary and $39.9K in other compensation.
Rankings
In 2019, Emil D. Kakkis' compensation ranked 1,491st out of 13,971 executives tracked by ExecPay. In other words, Kakkis earned more than 89.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,491 out of 13,971 | 89th |
Division Manufacturing | 535 out of 5,701 | 91st |
Major group Chemicals And Allied Products | 163 out of 2,200 | 93rd |
Industry group Drugs | 129 out of 1,886 | 93rd |
Industry Pharmaceutical Preparations | 96 out of 1,398 | 93rd |
Source: SEC filing on April 29, 2020.
Kakkis' colleagues
We found four more compensation records of executives who worked with Emil D. Kakkis at Ultragenyx Pharmaceutical in 2019.
2019
John Pinion
Ultragenyx Pharmaceutical
Chief Quality Officer and Executive Vice President, Translational Sciences
2019
Shalini Sharp
Ultragenyx Pharmaceutical
Chief Financial Officer
2019
Camille Bedrosian
Ultragenyx Pharmaceutical
Chief Medical Officer
2019
Thomas Kassberg
Ultragenyx Pharmaceutical